According to Yuyue Medical's announcement, Yuyue Holdings Co., Ltd., a wholly-owned subsidiary of the company, plans to subscribe for Class A1 shares of CFTC Paragon SP and CFTC Paramount SP under the CFTC Summit Fund SPC, with a total subscription amount of no more than HK$100 million. This investment does not need to be submitted to the company's board of directors or shareholders' meeting for review, and does not constitute a related transaction or major asset restructuring. The target fund mainly invests in high-quality PE to IPO projects in the fields of artificial intelligence, semiconductor chips, etc. This investment will not have a significant impact on the company's current financial situation and operating results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.